pharma · Non-small Cell Lung Cancer · Solid Tumors
BioNTech SE
BioNTech SE clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- An der Goldgrube 12, Mainz, Rhineland-Palatinate 55131, DE
- Founded
- 2008
- Employees
- 5,119
- Programs
- 23
- Drugs
- 35
- Patents
- 25
BioNTech SE projects
7 ClinicalTrials.gov programs sponsored by BioNTech SE.
BioNTech SE has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BNT116-01
BioNTech SE
Advanced non-small cell lung cancer
1 trial -
BNT164-01
BioNTech SE
Tuberculosis
1 trial -
BNT211-01
BioNTech SE
Solid Tumors
1 trial -
BNT314
BioNTech SE
Advanced or metastatic malignant solid tumors
1 trial -
BNT351-01
BioNTech SE
HIV-1 infection
1 trial -
Dose escalation trial of BNT152+153 in patients with cancer
BioNTech SE
Various solid tumors that are metastatic or unresectable
1 trial -
NTC-001
BioNTech SE
Metastatic melanoma
1 trial
Frequently asked questions
How many clinical projects does BioNTech SE have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.